Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA34176-254: Axatilimab + Ruxolitinib in Newly Diagnosed Chronic Graft-Versus-Host Disease
2022-502168-19-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of axatilimab and ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Primary endpoint: Overall response at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
axatilimabruxolitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2022-502168-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502168-19-00.